High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia

Am J Hematol. 2022 May;97(5):E171-E173. doi: 10.1002/ajh.26490. Epub 2022 Feb 11.

Authors

Hoda Pourhassan¹, Dongyun Yang², Michelle Afkhami³, Raju Pillai³, Brian Ball¹, Monzr Al Malki¹, Amandeep Salhotra¹, Haris Ali¹, Andrew Artz¹, Peter Curtin¹, Saro Armenian⁴, Anthony Stein¹, Stephen J Forman¹, Guido Marcucci¹, Vinod Pullarkat¹, Ryotaro Nakamura¹, Ibrahim Aldoss¹

Affiliations

¹ Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA.
² Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
³ Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
⁴ Department of Pediatrics, City of Hope, Duarte, California, USA.

PMID: 35132678
DOI: 10.1002/ajh.26490

No abstract available

Publication types

Letter

MeSH terms

Humans
Mutation
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Prevalence
Prognosis
Tumor Suppressor Protein p53* / genetics

Substances

TP53 protein, human
Tumor Suppressor Protein p53

Grants and funding

K12 CA001727/CA/NCI NIH HHS/United States